• Online Features  This Article  • PDF of this Correction  • Original article  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Intern Med. 2005;165:2541.

In the Original Investigation titled "Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study" by Brown et al, published in the May 23rd issue of the ARCHIVES (2005;165:1179-1184), the references were renumbered incorrectly in our publications office before publication. The list is correctly republished herein.

Also on page 1182 in the "Comment" section, paragraph 2, lines 11 to 16 should have read as follows:

"Justman et al⁸ recently reported a relative risk of incident self-reported DM of 2.0 (95% CI, 1.0- 4.1) when HIV-infected women receiving a PI were compared with an HIV-seronegative subgroup prospectively followed in the Women’s Interagency HIV Study."

On page 1183, "Comment" section, right hand column, lines 13 to 16 should have read as follows:

"Finally, we did not examine the effect of hepatitis C infection on incident or prevalent DM²⁷; we are investigating this important issue."

REFERENCES
1. Nightingale SL. From the Food and Drug Administration. JAMA. 1997;278:379. FREE FULL TEXT 2. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099. FULL TEXT | WEB OF SCIENCE | PUBMED 3. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160:2050-2056. FREE FULL TEXT 4. Walli R, Goebel FD, Demant T. Impaired glucose tolerance and protease inhibitors. Ann Intern Med. 1998;129:837-838. FREE FULL TEXT 5. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12:F167-F173. FULL TEXT | WEB OF SCIENCE | PUBMED 6. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-139. FREE FULL TEXT 7. Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002;34:1396-1405. FULL TEXT | WEB OF SCIENCE | PUBMED 8. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298-302. 9. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318. 10. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167. FREE FULL TEXT 11. Bondar RJ, Mead DC. Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Clin Chem. 1974;20:586-590. FREE FULL TEXT 12. American Diabetes Association. Clinical practice recommendations 2004. Diabetes Care. 2004;27:1-150. FREE FULL TEXT 13. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med. 2002;137:381-433. FREE FULL TEXT 14. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982. FREE FULL TEXT 15. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-706. FREE FULL TEXT 16. Harrell FE Regression Model Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer Publishing Co Inc; 2001. 17. Cox DR, Oakes D Analysis of Survival Data. New York, NY: Chapman & Hall; 1984. 18. Dever LL, Oruwari PA, Figueroa WE, O'Donovan CA, Eng RH. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Ann Pharmacother. 2000;34:580-584. ABSTRACT 19. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:20251-20254. FREE FULL TEXT 20. Dufer M, Neye Y, Krippeit-Drews P, Drews G Direct interference of HIV protease inhibitors with pancreatic beta-cell function. Naunyn Schmiedebergs Arch Pharmacol. 2004. 21. Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004;18:641-649. FULL TEXT | WEB OF SCIENCE | PUBMED 22. Martinez E, Domingo P, Galindo MJ, et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis. 2004;38:1017-1023. FULL TEXT | WEB OF SCIENCE | PUBMED 23. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;32:48-56. 24. Mauss S, Corzillius M, Wolf E, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med. 2002;3:49-55. FULL TEXT | PUBMED 25. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis. 2002;34:98-102. FREE FULL TEXT 26. Wu SC, Li CY, Ke DS. The agreement between self-reporting and clinical diagnosis for selected medical conditions among the elderly in Taiwan. Public Health. 2000;114:137-142. FULL TEXT | WEB OF SCIENCE | PUBMED 27. Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr. 2003;33:577-584.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Aspects of type 2 diabetes and related insulin-resistant States.
Bloomgarden
Diabetes Care 2006;29:732-740.
FULL TEXT